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Abstract 
 Deep learning methods have permeated into the research area of computer-aided drug design. 
The deep learning generative model and classical algorithm can be simultaneously used for three-
dimensional (3D) drug design in the 3D pocket of the receptor. Here, three aspects of MolAICal 
are illustrated for drug design: in the first part, the MolAICal uses the genetic algorithm, Vinardo 
score and deep learning generative model trained by generative adversarial net (GAN) for drug 
design. In the second part, the deep learning generative model is trained by drug-like molecules 
from the drug database such as ZINC database. The MolAICal invokes the deep learning 
generative model and molecular docking for drug virtual screening automatically. In the third part, 
the useful drug tools are added for calculating the relative properties such as Pan-assay 
interference compounds (PAINS), Lipinski's rule of five, synthetic accessibility (SA), and so on. 
Besides, the structural similarity search and quantitative structure-activity relationship (QSAR), 
etc are also embedded for the calculations of drug properties in the MolAICal. MolAICal will 
constantly optimize and develop the current and new modules for drug design. The MolAICal can 
help the scientists, pharmacists and biologists to design the rational 3D drugs in the receptor 
pocket through the deep learning model and classical programming. MolAICal is free of charge 
for any academic and educational purposes, and it can be downloaded from the website 
https://molaical.github.io.  
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Introduction 
With the technology development of computer-aided drug design (CADD), the deep learning 
method has been immersed in the research field of drug design such as the chemical syntheses [1], 
classification of drugs [2] and so on [3]. Deep learning and classical programming of CADD have 
their own advantages on the development and discovery of innovative drugs. The traditional 
machine learning methods include the support vector machine (SVM) [4], Bayesian algorithm [5], 
random forest (RF) [6], artificial neural networks (ANNs) [7, 8], etc. According to some research 
reports, machine learning shows a good way for drug discovery. For instance, the inhibitors of 
kallikrein 5 protease [9] are explored via the SVM method. The binding score between ligand and 
protein is a key factor for screening the potential compounds. RF-based scoring functions reveal 
the Pearson’s correlation coefficients ranging from 0.559 to 0.783 between experimental affinities 
and predicted values on basis of PDBbind database v2007 [10]. Some studies indicate that 
Bayesian algorithms can be used to identify the inhibitors of G-protein-coupled receptors [11], and 
so on. The ANNs have been reported to predict chemical immunotoxicity [12]. As current research 
reports, the deep learning method shows a better performance than the traditional machine 
learning methods [13-15]. The deep learning methods have popularly used in the area of drug 
virtual screening and de novo drug design [16-18]. The representative methods for de novo drug 
design include variational autoencoders (VAEs) [19] and generative adversarial net (GAN) [20, 
21]. The objective-reinforced generative adversarial networks (ORGAN) is designed with the 
generator that produces the molecules to cheat the discriminator based on the reinforcement and 
adversarial learning methods [22]. The ORGAN mainly trains the deep learning model based on 
the SMILES sequences of ligands. The molecular graph is another way to profile the molecules 
with nodes and edges that correspond to the atoms and bonds of molecule. MolGAN [23] is a deep 
learning program that can be used to train molecular generative model based on molecular graph. 
The MolGAN contains GAN and VAEs for training the drug-like molecules through the 
annotation matrix and dense adjacency tensor. Besides, the research reports shows a good way to 
carry out drug virtual screening by SVM, molecular docking and molecular mechanics/generalized 
Born surface area (MM/GBSA), etc [24].  
The deep learning model and classical programming have different ways for drug design. The 
deep learning focuses on training rules of drug design based on input and output data of drugs. 
The well-trained model can be used to design drugs directly. In contrast, the traditional CADD 
software needs the algorithm rules and relative input data to design the drugs. The LigBuilder 
[25], OpenGrowth [26] and AutoDock Vina [27] are the popular drug design software. The 
LigBuilder and OpenGrowth develop the potential candidate drugs via the fragmented growth or 
link method that belongs to one branch of de novo drug design methods. The AutoDock Vina 
designs the ligands through molecular docking that is one way of virtual screening methods. The 
traditional CADD software shows a good performance for drug design. Especially, the AutoDock 
Vina shows the best scoring power according to the reported experiments about the ligands 
assessment in the receptor pocket [28]. The deep learning can learn the molecular characteristics 
with one-dimensional (1D) SMILES sequence, two-dimensional (2D) molecular graph and 
molecular graph incorporating three-dimensional (3D) structural information [29]. The classical 
programming can design the 3D ligands in the receptor pocket directly. In this case, the MolAICal 
is preliminarily designed on basis of deep learning and classical programming. The MolAICal soft 
package mainly focuses on three aspects of development and research. In the first part, the 
MolAICal is designed based on the de novo drug design method and deep learning model that is 
trained on the fragments of appointed special drugs such as Food and Drug Administration (FDA)-
approved drugs. In the second part, the MolAICal contains the modules of virtual screening and 
deep learning model that is trained on drug-like ligands of appointed special database such as 
ZINC database. In the third part, the useful tools for drug filter, prediction, etc. are developed in 
the MolAICal software for drug discovery. The main part of MolAICal is written by JAVA 
program that derives many useful libraries such as Chemistry Development Kit (CDK) [30], 
Ambit JAVA library, etc. MolAICal uses JAVA parallelstream to invoke multicore CPU for 
designing drugs concurrently. MolAICal will try its best to take advantage of the drug design 
method of deep learning model and classical programming for drug discovery. The MolAICal 
supplies an effective way for 3D ligand design in the receptor pocket.  
 
 
Figure 1. The module of MolAICal contains deep learning and classical programming methods. 
 
Results and Discussion 
Deep learning and de novo methods for drug design 
In the first module, MolAICal focuses on the method development of deep learning generative 
model and de novo drug design. As shown in Figure 1, the deep learning generative model is an 
important direction of research and development of MolAICal based on SMILES sequence and 
molecular graph. The effective and stable training methods can improve the accuracy rate of drug 
discovery. The popular training methods such as GAN are picked up for training the generative 
model of ligands and fragments in the current version of MolAICal. The MolAICal will further 
optimize the current training method GAN, and employ the new advanced technology for training 
generative models. In addition, the spatial structural information of ligand and receptor is an 
important factor for rational drug design. The deep learning generative model incorporating 3D 
structural information can show the state-of-the-art way to produce the molecules with high 3D 
similarity to the determined ligand of the receptor. MolAICal will further develop and train the 
excellent generative model incorporating 3D structural information for drug design. Meanwhile, the 
MolAICal also employs classical programming such as fragment growth for drug design based on 
the output fragments of deep learning generative model (see Figure 1). In the process of the drug 
design of MolAICal, the initial fragment is chosen as the started fragment in the 3D pocket of the 
receptor. The next fragment grows on the previous ligand fragment. The growth algorithm and 
binding score play an important role in the evaluation of drug design. MolAICal will further 
optimize the growth algorithm and develop the superior binding score based on the PDBbind 
database. Besides, MolAICal also supplies the user-defined seed fragments for de novo drug design. 
Generally, deep learning and classical programming are the development aspects of the MolAICal. 
The ultimate goal is that MolAICal can try its best to take advantage of the deep learning and 
classical programming for drug design. 
 
 
Figure 2. The module of MolAICal contains deep learning and drug virtual screening method. 
 
Deep learning and virtual screening method for drug design 
 In the second module, the deep learning generative model and virtual screening method are 
introduced for drug screening in the MolAICal. MolAICal provides two drug design ways that 
screen ligands in the 3D pocket of receptors based on the known drug database and generated 
database by deep learning model. First of all, the high-quality ligand sets can promote the speed of 
new drug discovery. As shown in Figure 2, MolAICal employs the deep learning generative model 
for producing the drug-like database. The deep learning generative model can generate high-quality, 
novel, synthesizable, diversity and drug-like ligands. Secondly, because the ligands are the SMILES 
format in the generated drug database, the software Open Babel [31] is employed to transform the 
3D structure from the SMILES format ligands on basis of Merck Molecular Force Field 94 
(MMFF94). The MolAICal will further develop its module to satisfy the requirement of molecular 
format conversion for drug design. Thirdly, the drug virtual screening is performed on the 3D 
receptor pocket based on the generated drug database by invoking the molecular docking program 
Autodock Vina (see Figure 2). The MolAICal will further update Autodock Vina to another version 
named MACDock. The MACDock will improve its performance based on "scoring power", 
"ranking power", "docking power", and "screening power". In addition, drug virtual screening based 
on the known ligands database is also added in MolAICal. Lastly, the MM/GBSA is a kind of 
recognized accurate way to assess the binding free energy of protein-ligand, protein-protein, and so 
on [32]. MolAICal provides a way to calculate the MM/GBSA based on the output results of 
molecular dynamics simulations that are carried out by software NAMD. The score functions which 
can be used to assess the affinities of ligands in the receptor pocket are an important development 
area in MolAICal. The MolAICal will develop its molecular format transformation and 3D 
coordinate generation based on the force field. The drug generative model and molecular docking 
program, etc are also added in the development plan of MolAICal.   
 
 
Figure 3. The useful tools of MolAICal for drug design. 
 
Useful tools for drug design 
 The deep learning model, classical programming and Vinardo score can be used to select the 
good affinity ligands in soft package MolAICal. However, it still needs to evaluate absorption, 
distribution, metabolism, excretion, toxicity, drug-likeness, etc of drugs. In the current version of 
MolAICal, Lipinski's rule of five (RO5), pan-assay interference compounds (PAINS) and 
synthetic accessibility (SA) are embedded to assess the drug-likeness of ligands (see Figure 3). 
The parameters and methods of these filter rules will further be optimized and improved in 
MolAICal. For example, as the research report of FDA approved oral drugs [33], the RO5 has 
substantially changed its cutoff values of rotatable bonds, molecular weight, and hydrogen bond 
acceptors. In this case, the parameters of RO5 need to be updated according to the research report. 
Besides, MolAICal also contains useful drug design tools such as quantitative structure-activity 
relationship (QSAR), ligand similarity search (SS) and potential of mean force (PMF) (see Figure 
3). These kinds of tools can be quickly used to screen or evaluate the drugs. The MolAICal will 
further develop the medicinal chemistry filters (MCFs) [34], descriptor MCE-18 [35], weak 
interaction [36] and so on. Generally, MolAICal will continually develop new and effective tools 
for drug filter and design.  
 
Conclusions 
  In this paper, the main three modules of MolAICal are introduced for drug design. For the first 
module, the deep learning and de novo methods are developed for fragment growth in the 3D 
pocket of the receptor. For the second module, deep learning and virtual screening method are 
added for drug screening in the 3D pocket of the receptor. Both of two modules in MolAICal can 
be also used to design drugs in the receptor pocket based classical programming independently. 
For the third module, the MolAICal focuses on the development of effective and useful tools for 
drug filter and design. In total, the MolAICal will continually optimize and develop new methods 
for drug design. The ultimate aim is that MolAICal can help scientists to find new drugs efficiently.  
 
 
Materials and methods 
Deep learning 
In the current version, the Wasserstein generative adversarial networks (WGANs) [37] are 
picked up to train the deep learning generative model of MolAICal. The WGANs can be used to 
calculate the difference of probability distributions between the fraud and genuine drugs data 
distribution (see equation 1).  
𝑊(ℙ𝑟 , ℙ𝜃) = 𝔼𝑥~ℙ𝑟[𝑓(𝑥)] − 𝔼𝑥~ℙ𝜃[𝑓(𝑥)]||𝑓||𝐿≤1
sup  
                   (1) 
To obtain the best optimization of equation 1, the solution of WGANs is shown in equation 2: 
min
𝐺
 max
𝐷
 𝔼𝑥~ℙ𝑟[𝐷(𝑥)] − 𝔼𝑧~𝑝(𝑧)[𝐷(𝐺(𝑧)]                       (2) 
Where the D and G are the discriminator and generator, respectively. The discriminator D 
increases the distinguishable probability of genuine data and decrease the indistinguishable 
probability of fraud data in the training process. The stable training WGANs is added to the 
development plan of MolAICal.  
 
Classical programming 
The genetic algorithm is used for de novo drug design. The initial fragment is chosen from 
the part of known ligand in the receptor pocket or generated by appointed SMILES around the 
atom of key residue. The next fragment grows on the previous fragment through the perturbation 
search of the Fibonacci or random algorithm. The Fibonacci points are distributed on the sphere 
according to equation 3:  
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Where xi, yi and zi represent the position of sphere points in the coordinate system. The letter N 
represents the number of produced points that can be appointed by users. The operators' crossover 
and mutation of genetic algorithm (GA) are used to optimize the ligands in the receptor pocket. The 
MolAICal also employs classical programming for drug virtual screening and unwanted ligands 
filtering. MolAICal will optimize these methods, and further add the new effective classical 
programming for drug design.  
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